Treatment of Chronic Pain With Various Buprenorphine Formulations: A Systematic Review of Clinical Studies

@article{Aiyer2018TreatmentOC,
  title={Treatment of Chronic Pain With Various Buprenorphine Formulations: A Systematic Review of Clinical Studies},
  author={Rohit Aiyer and Amitabh Gulati and S. Gungor and Anuj Bhatia and Neel Mehta},
  journal={Anesthesia \& Analgesia},
  year={2018},
  volume={127},
  pages={529–538}
}
Clinical studies demonstrate that buprenorphine is a pharmacologic agent that can be used for the treatment of various types of painful conditions. This study investigated the efficacy of 5 different types of buprenorphine formulations in the chronic pain population. The literature was reviewed on PubMed/MEDLINE, EMBASE, Cochrane Database, clinicaltrials.gov, and PROSPERO that dated from inception until June 30, 2017. Using the population, intervention, comparator, and outcomes method, 25… 
View on Wolters Kluwer
progettoasco.it
36 Citations
Highly Influential Citations
1
Background Citations
5
Results Citations
1

Tables from this paper

36 Citations

Citation Type

Citation Type

Tapentadol, Buprenorphine, and Levorphanol for the Treatment of Neuropathic Pain: a Systematic Review
TLDR
The role of tapentadol, buprenorphine, and levorphanol for neuropathic pain conditions requires robust research including randomized controlled trials to evaluate their efficacy and safety.
A narrative review of buprenorphine in adult cancer pain
TLDR
A narrative review of pathophysiological pathways of pain in cancer, how they are treated, and the unique properties of buprenorphine shows strong data for transdermal bupenorphine and promising data for sublingual bupRenorphine.
Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion
TLDR
The overall consensus of the panel was that buprenorphine is a unique Schedule III opioid with favorable pharmacologic properties and a safety profile that may be desirable for chronic pain management.
Buprenorphine/naloxone induction for treatment of acute on chronic pain using a micro-dosing regimen: A case report
TLDR
A postoperative neurosurgical inpatient who was referred to the team for pain management in the context of chronic pain was successfully transitioned to buprenorphine/naloxone, replacing all other opioid analgesia, without a period of opioid withdrawal using a micro-dosing induction regimen.
Opioid Treatments for Chronic Pain
TLDR
Outcomes of interest were pain, function, health status/quality of life, mental health outcomes, sleep, doses of opioid used (for comparisons involving opioids and nonopioid therapy) and harms.
Multimodal Treatment Options, Including Rotating to Buprenorphine, Within a Multidisciplinary Pain Clinic for Patients on Risky Opioid Regimens: A Quality Improvement Study
TLDR
Results suggest the ORC was effective in reducing total prescribed opioid doses and in transitioning patients to partial-agonist therapy, but PCP adoption strategies are needed.
Treating Chronic Pain: Is Buprenorphine the (or Even an) Answer?
TLDR
Buprenorphine may hold the potential to be a “silver bullet” for treating chronic pain—or, at the very least, another tool in the arsenal, in the face of the opioid epidemic.
Applying Best Practice Guidelines on Chronic Pain in Clinical Practice—Treating Patients Who Suffer From Pain and Addiction
  • K. Heinzerling
  • Medicine, Psychology
    The Assessment and Treatment of Addiction
  • 2019
A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain
TLDR
The unique pharmacodynamic and pharmacokinetic properties of buprenorphine contribute to its effective pain relief and a potentially favorable safety profile for chronic pain management.
Pain management in patients with chronic kidney disease and end-stage kidney disease
TLDR
Buprenorphine appears to be a promising and safer option due to its partial agonism at the mu opioid receptor, and should be first-line approaches for pain management in patients with kidney disease.
...
1
2
3
4
...

References

SHOWING 1-10 OF 46 REFERENCES
Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial.
Buprenorphine for neuropathic pain in adults.
TLDR
There was insufficient evidence to support or refute the suggestion that buprenorphine has any efficacy in any neuropathic pain condition.
Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patients with chronic pain. A randomised, double-blind, placebo-controlled study
AbstractThis randomised, double-blind, placebo-controlled study evaluated the efficacy and tolerability of buprenorphine TDS, a new transdermal formulation of the opioid analgesic buprenorphine.…
Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain.
Transdermal Buprenorphine Relieves Neuropathic Pain: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial in Diabetic Peripheral Neuropathic Pain
TLDR
Transdermal buprenorphine, when tolerated, is an effective therapy for DPNP and provides another option to manage this challenging painful condition, and nausea and constipation need to be managed proactively to optimize treatment outcomes.
A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans seven-day patches) with buprenorphine sublingual tablets (Temgesic) in patients with osteoarthritis pain.
Comparisons of Analgesic Potency and Side Effects of Buprenorphine and Buprenorphine With Ultra-low-dose Naloxone
TLDR
These findings suggest that BUP + ULDN is not more effective in reducing pain than BUP, and combinations of opioids with ultra-low doses of the opioid antagonist naloxone may enhance the analgesic effect with increased safety.
Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study.
A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain.
TLDR
Significant relief in the intensity of pain was achieved for the initial 6 months and the effects stabilized in the remainder of the study in both groups, and a higher equipotent dose of fentanyl was required for comparable pain relief.
...
1
2
3
4
5
...